Alvotech (ALVO) Expected to Announce Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $109.6360 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Alvotech (NASDAQ:ALVO) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.50). The company had revenue of $173.20 million for the quarter, compared to analysts’ expectations of $162.20 million. Alvotech had a net margin of 4.74% and a negative return on equity of 11.92%. On average, analysts expect Alvotech to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alvotech Stock Performance

ALVO opened at $3.46 on Monday. The company has a fifty day moving average of $3.64 and a 200 day moving average of $4.87. Alvotech has a fifty-two week low of $3.03 and a fifty-two week high of $11.85. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of 34.60 and a beta of 0.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Magnetar Financial LLC bought a new position in Alvotech during the third quarter valued at $86,000. Orion Porfolio Solutions LLC bought a new stake in shares of Alvotech in the 3rd quarter worth about $92,000. Bank of America Corp DE boosted its stake in shares of Alvotech by 218.0% during the 2nd quarter. Bank of America Corp DE now owns 16,623 shares of the company’s stock worth $152,000 after purchasing an additional 11,395 shares during the period. Amundi boosted its stake in shares of Alvotech by 71.0% during the 3rd quarter. Amundi now owns 19,416 shares of the company’s stock worth $167,000 after purchasing an additional 8,059 shares during the period. Finally, Stifel Financial Corp bought a new position in Alvotech during the 4th quarter valued at about $108,000.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen raised Alvotech from a “sell” rating to a “hold” rating in a research note on Saturday, April 18th. UBS Group dropped their price objective on shares of Alvotech from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Zacks Research upgraded shares of Alvotech from a “strong sell” rating to a “hold” rating in a report on Thursday, March 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Alvotech in a research report on Monday, April 20th. Finally, Barclays dropped their price target on Alvotech from $5.00 to $4.00 and set an “underweight” rating for the company in a research report on Tuesday, March 24th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $7.60.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).